Sulin Zhang

Sulin Zhang

Auto-generated profile, based on publicly available information

Sulin Zhang

School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
LCLifan Chen
Lifan Chen
ZFZisheng Fan
Zisheng Fan
JCJie Chang
Jie Chang
RYRuirui Yang
Ruirui Yang
HHHui Hou
Hui Hou
MZMingyue Zheng
Mingyue Zheng
Drug development based on target proteins has been a successful approach in recent decades. However, the conventional structure-based drug design (SBDD) pipeline is a complex, human-engineered process with multiple independently optimized steps. Here, we propose a sequence-to-drug concept for computational drug design based on protein sequence information by end-to-end differentiable learning. We validate this concept in three stages. First, we design TransformerCPI2.0 as a core tool for the concept, which demonstrates generalization ability across proteins and compounds. Second, we interpret the binding knowledge that TransformerCPI2.0 learned. Finally, we use TransformerCPI2.0 to discover new hits for challenging drug targets, and identify new target for an existing drug based on an inverse application of the concept. Overall, this proof-of-concept study shows that the sequence-to-drug concept adds a perspective on drug design. It can serve as an alternative method to SBDD, particularly for proteins that do not yet have high-quality 3D structures available.

27 November 2024 in Nature Methods
Verified
Journal Article
Closed access
PDF file
DCDuanhua Cao
Duanhua Cao
MCMingan Chen
Mingan Chen
RZRunze Zhang
Runze Zhang
ZWZhaokun Wang
Zhaokun Wang
MHManlin Huang
Manlin Huang
MZMingyue Zheng
Mingyue Zheng

25 June 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
XTXiaochu Tong
Xiaochu Tong
NQNing Qu
Ning Qu
XKXiangtai Kong
Xiangtai Kong
SNShengkun Ni
Shengkun Ni
JZJingyi Zhou
Jingyi Zhou
MZMingyue Zheng
Mingyue Zheng
Artificial intelligence transforms drug discovery, with phenotype-based approaches emerging as a promising alternative to target-based methods, overcoming limitations like lack of well-defined targets. While chemical-induced transcriptional profiles offer a comprehensive view of drug mechanisms, inherent noise often obscures the true signal, hindering their potential for meaningful insights. Here, we highlight the development of TranSiGen, a deep generative model employing self-supervised representation learning. TranSiGen analyzes basal cell gene expression and molecular structures to reconstruct chemical-induced transcriptional profiles with high accuracy. By capturing both cellular and compound information, TranSiGen-derived representations demonstrate efficacy in diverse downstream tasks like ligand-based virtual screening, drug response prediction, and phenotype-based drug repurposing. Notably, in vitro validation of TranSiGen’s application in pancreatic cancer drug discovery highlights its potential for identifying effective compounds. We envisage that integrating TranSiGen into the drug discovery and mechanism research holds significant promise for advancing biomedicine.

6 June 2024 in Nature Machine Intelligence
Verified
Journal Article
Closed access
PDF file
DCDuanhua Cao
Duanhua Cao
GCGeng Chen
Geng Chen
JJJiaxin Jiang
Jiaxin Jiang
JYJie Yu
Jie Yu
RZRunze Zhang
Runze Zhang
MZMingyue Zheng
Mingyue Zheng

22 October 2021 in Protein & Cell
Verified
Journal Article
Open access
PDF file
FZFeisheng Zhong
Feisheng Zhong
XWXiaolong Wu
Xiaolong Wu
RYRuirui Yang
Ruirui Yang
XLXutong Li
Xutong Li
DWDingyan Wang
Dingyan Wang
MZMingyue Zheng
Mingyue Zheng
A fundamental challenge that arises in biomedicine is the need to characterize compounds in a relevant cellular context in order to reveal potential on-target or off-target effects. Recently, the fast accumulation of gene transcriptional profiling data provides us an unprecedented opportunity to explore the protein targets of chemical compounds from the perspective of cell transcriptomics and RNA biology. Here, we propose a novel Siamese spectral-based graph convolutional network (SSGCN) model for inferring the protein targets of chemical compounds from gene transcriptional profiles. Although the gene signature of a compound perturbation only provides indirect clues of the interacting targets, and the biological networks under different experiment conditions further complicate the situation, the SSGCN model was successfully trained to learn from known compound-target pairs by uncovering the hidden correlations between compound perturbation profiles and gene knockdown profiles. On a benchmark set and a large time-split validation dataset, the model achieved higher target inference accuracy as compared to previous methods such as Connectivity Map. Further experimental validations of prediction results highlight the practical usefulness of SSGCN in either inferring the interacting targets of compound, or reversely, in finding novel inhibitors of a given target of interest.

19 November 2024 in Advanced Science
Verified
Journal Article
Open access
YLYadan Liu
Yadan Liu
JYJialin Ye
Jialin Ye
ZFZisheng Fan
Zisheng Fan
XWXiaolong Wu
Xiaolong Wu
YZYinghui Zhang
Yinghui Zhang
SZSulin Zhang
Sulin Zhang
Ginkgo biloba extract is reported to have therapeutic effects on aging‐related disorders. However, the specific component responsible for this biological function and its mechanism of action remain largely unknown. This study finds that Ginkgetin, an active ingredient of Ginkgo biloba extract, can alleviate cellular senescence and improve pathologies in multiple tissues of aging mice. To reveal the molecular mechanism of Ginkgetin's anti‐aging effect, a graph convolutional network‐based drug “on‐target” pathway prediction algorithm for prediction is employed. The results indicate that the cGAS‐STING pathway may be a potential target for Ginkgetin. Subsequent cell biological and biophysical data confirmed that Ginkgetin directly binds to the carboxy‐terminal domain of STING protein, thereby inhibiting STING activation and signal transduction. Furthermore, in vivo pharmacodynamic data showed that Ginkgetin effectively alleviates systemic inflammation in Trex1−/− mice and inhibits the abnormally activated STING signaling in aging mouse model. In summary, this study, utilizing an artificial intelligence algorithm combined with pharmacological methods, confirms STING serves as a critical target for Ginkgetin in alleviating inflammation and senescence. Importantly, this study elucidates the specific component and molecular mechanism underlying the anti‐aging effect of Ginkgo biloba extract, providing a robust theoretical basis for its therapeutic use.